Drug intelligence / Profile preview

AZD6563

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

AZD6563 is an investigational mRNA-based vaccine developed by AstraZeneca for the prevention of COVID-19. It is designed to encode the spike protein of the SARS-CoV-2 virus, specifically targeting the Omicron XBB.1.5 variant. The vaccine is part of AstraZeneca's next-generation COVID-19 vaccine portfolio, moving beyond the viral vector platform (AZD1222) into mRNA technology. It is currently being evaluated in Phase I clinical trials (such as the ARTEMIS-C study) to assess its safety and immunogenicity compared to earlier mRNA vaccine candidates like AZD9838.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on AZD6563.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD6563.

Explore the full profile